ATHE - Spark Newswire

1 minute read

Alterity’s Parkinson’s Candidate Prevents Loss Of Brain Cells In Animal Model

Yesterday, 1:43 PM

Alterity Therapeutics (NASDAQ:ATHE) announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective…

ATHE

1 minute read

Here’s Why Alterity Therapeutics Shares Are Moving

By Henry Khederian

Yesterday, 12:16 PM

Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading higher by 5.67% to $4.12 Monday morning after the company announced ATH434 prevents loss of brain cells in Parkinson's Disease animal model.

ATHE

1 minute read

News

Alterity Therapeutics Announced Earlier ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

By Charles Gross

Yesterday, 5:49 AM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson's disease (PD).

ATHE

2 minute read

5 Most Expensive Health Care Stocks You Should Worry About

By Lisa Levin

January 12, 10:01 AM

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

ATHE

1 minute read

News

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial In The United States For The Treatment Of Individuals With Multiple System Atrophy

By Charles Gross

January 8, 8:45 PM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.

ATHE

1 minute read

Alterity Therapeutics Announced 1-for-10 Reverse ADS Split

By Charles Gross

January 6, 6:08 AM

Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the "ADS Ratio") from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the "ADS Ratio Change"). The ADS Ratio Change will be effective on January 9, 2023.

ATHE

1 minute read

News

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

By Charles Gross

December 29, 11:26 AM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office (USPTO). The patent was allowed following expedited review by the USPTO.

ATHE

2 minute read

News

Alterity Therapeutics Announced Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting

By Charles Gross

November 7, 6:27 AM

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, 2022.

ATHE

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

October 20, 5:57 PM

Gainers Nuwellis (NASDAQ:NUWE) stock rose 13.9% to $0.28 during Thursday's after-market session. The company's market cap stands at $8.9 million.

ATHE

1 minute read

Here’s Why Alterity Therapeutics Shares Are Volatile

By Henry Khederian

September 20, 11:30 AM

Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading sharply lower by 14.29% to $0.48, reversing following earlier strength, after the company announced the approval of its Investigational New Drug application by the FDA to allow evaluation of ATH434 in individuals with Multiple System Atro

ATHE

Feed Symbols: ATHE